Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Место β-блокаторов и диуретиков в Российских рекомендациях по артериальной гипертонии 2008 года - Журнал Системные Гипертензии №1 (2009)
Место β-блокаторов и диуретиков в Российских рекомендациях по артериальной гипертонии 2008 года
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Ключевые слова: артериальная гипертензия, β-блокаторы
________________________________________________
Полный текст
Список литературы
1. Диагностика и лечение артериальной гипертензии. Российские рекомендации. Кардиоваск. тер. и проф. Прил. 2. 2008; 7 (6).
2. ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105–87.
3. Task Force Members, Lopez-Sendon J, Swedberg K, McMurray J et al. Expert consensus document on β–adrenergic receptor blockers. The Task Force on Beta–Blockers of the European Society of Cardiology. Eur Heart J 2004; 25: 1341–62.
4. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the swidish trial in old patients with hypertension (STOP–Hypertension). Lancet 19991; 338: 1281–5.
5. Olsson G, Tuomilehto J, Berglund G et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY study. Am J Hypertens 1991; 4: 151–8.
6. Wiysonge CS, Bradley H, Mayosi BM et al. Beta blockers for hypertension. Cochrane Database Review 2007; 1: CD002003.
7. Egstrup et al. The antianginal efficacy and tolerability of controlled-release metoprolol once daily: a comparison with conventional metoprolol tablets twice daily. J Clin Pharmacol 1988; 33.
8. Остроумова О.Д., Рыкова А.М. и др. Выбор антигипертензивных препаратов у больных с сочетанием артериальной гипертензии и ишемической болезни сердца: фокус на β-блокаторы. Consilium Medicum 2007; 9 (5).
9. Frishman WH. Postinfarction survival: role of beta-adrenic blocade, in Fuster V (ed): Atherosclerosis and Coronary Artery Disease. Philadelphia, Lippencott 1996: 1205–14.
10. Omvik P et al. Equal efficacy and improved tolerability with 50 mg controlled-release metoprolol compared with 100 mg conventional metoprolol in hypertensive patients. Am J Ther 1994; 1: 65–73.
11. Wiklund O, Hulthe J, Wikstrand J et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33: 572–7.
12. Post-stroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. Clin Med J 1995; 108 (9): 710–7.
13. Beckett NS, Peters R, Fletcher AE et al. The HYVET Study Group. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358 (18): 1887–98.
14 Gueyffier F, Bulpitt C, Boissel JP et al.; the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999; 353 (9155): 793–6.
15. Messerli FH, Mancia G, Conti CR et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144 (12): 884–93.
2. ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105–87.
3. Task Force Members, Lopez-Sendon J, Swedberg K, McMurray J et al. Expert consensus document on β–adrenergic receptor blockers. The Task Force on Beta–Blockers of the European Society of Cardiology. Eur Heart J 2004; 25: 1341–62.
4. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the swidish trial in old patients with hypertension (STOP–Hypertension). Lancet 19991; 338: 1281–5.
5. Olsson G, Tuomilehto J, Berglund G et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY study. Am J Hypertens 1991; 4: 151–8.
6. Wiysonge CS, Bradley H, Mayosi BM et al. Beta blockers for hypertension. Cochrane Database Review 2007; 1: CD002003.
7. Egstrup et al. The antianginal efficacy and tolerability of controlled-release metoprolol once daily: a comparison with conventional metoprolol tablets twice daily. J Clin Pharmacol 1988; 33.
8. Остроумова О.Д., Рыкова А.М. и др. Выбор антигипертензивных препаратов у больных с сочетанием артериальной гипертензии и ишемической болезни сердца: фокус на β-блокаторы. Consilium Medicum 2007; 9 (5).
9. Frishman WH. Postinfarction survival: role of beta-adrenic blocade, in Fuster V (ed): Atherosclerosis and Coronary Artery Disease. Philadelphia, Lippencott 1996: 1205–14.
10. Omvik P et al. Equal efficacy and improved tolerability with 50 mg controlled-release metoprolol compared with 100 mg conventional metoprolol in hypertensive patients. Am J Ther 1994; 1: 65–73.
11. Wiklund O, Hulthe J, Wikstrand J et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33: 572–7.
12. Post-stroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. Clin Med J 1995; 108 (9): 710–7.
13. Beckett NS, Peters R, Fletcher AE et al. The HYVET Study Group. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358 (18): 1887–98.
14 Gueyffier F, Bulpitt C, Boissel JP et al.; the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999; 353 (9155): 793–6.
15. Messerli FH, Mancia G, Conti CR et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144 (12): 884–93.
Авторы
И.Е.Чазова, Л.Г.Ратова*
ФГУ РКНПК Федерального агентства по высокотехнологичной медицинской помощи, Москва
*lratova@mail.ru
*lratova@mail.ru
ФГУ РКНПК Федерального агентства по высокотехнологичной медицинской помощи, Москва
*lratova@mail.ru
________________________________________________
*lratova@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.